Research reveals smokeless tobacco users at higher risk of a heart attack or stroke

NewsGuard 100/100 Score

People who use smokeless tobacco products like snus have a slightly higher risk of having a fatal heart attack or stroke, according to research published on bmj.com today.

In the past few decades there has been an increase in the number of people in Europe and North America using smokeless tobacco, particularly among people younger than 40. Given that these products are being promoted as 'safer' alternatives to smoking cigarettes, the number of individuals using them is set to increase, says the study.

The research team, led by Dr Paolo Boffetta at International Agency for Research on Cancer in France, analysed the results of 11 studies carried out in Sweden and North America on the use of smokeless tobacco products and the risk of developing or dying from a heart attack or stroke.

Differences in study design and quality were taken into account to minimise bias.

They found a small increased risk of death from a heart attack or stroke among users of smokeless tobacco products compared with non-users. Smokeless tobacco caused 0.5% of all heart attacks in the United States and 5.6% in Sweden. The products were also the cause of 1.7% of stroke deaths in the United States and 5.4% in Sweden.

The authors conclude that, although the magnitude of the excess risk, particularly for fatal myocardial infarction, was small, the consistency of the results among studies and their robustness with respect to study design and quality added to their credibility.

If the association is real, the authors believe that its public health and clinical implications might be substantial and they call for more research in this area.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses